Liposomal Anthracyclines: Facing the Clinical Challenge

Abstract

The field of liposomal anthracyclines has been growing steadily since an initial paper published by Forssen and Tokes in 1979 (1). Rather than the up and down waves of many new experimental approaches to cancer therapy, the field of liposomal anthracyclines has grown at quite a constant rate in a crescendo fashion. A detailed look at the field reveals a close link between the flow of technological improvement and important changes in the strategy of development of liposomal anthracyclines which have taken place in the last decade.